Geron up big in today's trading

Geron (GERN +23%) is up 23% on 4x normal volume as investors storm back into the stock after last Wednesday's collapse.

Market chatter believes shares are oversold due to the perception that the FDA-mandated clinical hold for Imetelstat will be temporary. Most of the observed elevations in liver enzymes are Grade 1 with no progression over prolonged exposure.

The mean analyst recommendation is Hold.

Comments (2)
  • pat45
    , contributor
    Comments (470) | Send Message
    I am taking my GERN profit... short wait with FDA is a year.
    18 Mar 2014, 01:34 PM Reply Like
  • pat walsh
    , contributor
    Comments (347) | Send Message
    I bot at 1.47 and 1.52.I have the patience of a saint.
    18 Mar 2014, 06:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs